REG - Scancell Hlds - Extension of exercise period for CEO share options

Scancell HoldingsAnnouncement

13/07/2023 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230713:nRSM9278Fa&default-theme=true

RNS Number : 9278F  Scancell Holdings Plc  13 July 2023

13 July
2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Extension of exercise period for CEO share options

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, announces that the exercise
period for 3.85 million share options awarded to Lindy Durrant, Chief
Executive Officer of the Company, on 30 July 2020 will be extended from 30
July 2023 to 30 July 2026.

 

These options have an exercise price of 4.5 pence each. All other conditions
of the award remain the same.

 

The extension of the expiry date for the share options amounts to a related
party transaction within the meaning of the AIM Rules for Companies. The
Directors who are independent of the related party transaction (being all the
Directors of the Company other than Lindy Durrant) having consulted with
Stifel, the Company's nominated adviser, consider this proposed extension of
the expiry date to be fair and reasonable insofar as the shareholders of the
Company are concerned.

 

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications                                           +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                   scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFDSADEDSEFW